Cargando…

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children

BACKGROUND: Ceftazidime-avibactam is an effective agent for the treatment of tuberculosis (TB) but requires frequent administration because of a short half-life. Due to a longer half-life, ceftriaxone could allow intermittent dosing. METHODS: First, we identified the MIC of ceftriaxone with 15 mg/L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Shashikant, van Zyl, Johanna, Cirrincione, Kayle, Martin, Katherine, Thomas, Tania, Deshpande, Devyani, Alffenaar, Jan-William, Seddon, James A., Gumbo, Tawanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Antimicrobial Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654946/ https://www.ncbi.nlm.nih.gov/pubmed/32773662 http://dx.doi.org/10.1097/INF.0000000000002857

Ejemplares similares

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2017)

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2018)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021)

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
por: Deshpande, Devyani, et al.
Publicado: (2016)

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
por: Gumbo, Tawanda, et al.
Publicado: (2023)

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy
por: Deshpande, Devyani, et al.
Publicado: (2022)

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
por: Deshpande, Devyani, et al.
Publicado: (2016)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
por: Deshpande, Devyani, et al.
Publicado: (2016)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
por: Deshpande, Devyani, et al.
Publicado: (2020)

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases
por: Deshpande, Devyani, et al.
Publicado: (2016)

Inoculum-dependent bactericidal activity of a Mycobacterium tuberculosis MmpL3 inhibitor
por: Berube, Bryan, et al.
Publicado: (2023)

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2017)

Dissemination and genome analysis of high-level ceftriaxone-resistant penA 60.001 Neisseria gonorrhoeae strains from the Guangdong Gonococcal antibiotics susceptibility Programme (GD-GASP), 2016–2019
por: Lin, Xiaomian, et al.
Publicado: (2022)

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
por: Swaminathan, Soumya, et al.
Publicado: (2016)

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Draft Genome Sequence of Ciprofloxacin and Ceftriaxone Resistant Campylobacter jejuni MM26-781 Assigned to Novel ST Isolated From Common Pigeon in Lithuania
por: Aksomaitiene, Jurgita, et al.
Publicado: (2019)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis
por: Batt, Sarah M., et al.
Publicado: (2023)

Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead
por: Gumbo, Tawanda, et al.
Publicado: (2016)

Cryo-EM structure of Mycobacterium tuberculosis 50S ribosomal subunit bound with clarithromycin reveals dynamic and specific interactions with macrolides
por: Zhang, Wen, et al.
Publicado: (2022)

Replicative transposition contributes to the evolution and dissemination of KPC-2-producing plasmid in Enterobacterales
por: Tang, Yu, et al.
Publicado: (2021)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Mallikaarjun, Suresh, et al.
Publicado: (2020)

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence
por: Pasipanodya, Jotam G., et al.
Publicado: (2017)

CpxR promotes the carbapenem antibiotic resistance of Klebsiella pneumoniae by directly regulating the expression and the dissemination of bla(KPC) on the IncFII conjugative plasmid
por: Liu, Zhiyuan, et al.
Publicado: (2023)

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
por: Boorgula, Gunavanthi D., et al.
Publicado: (2021)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Disseminated tuberculosis with tuberculous meningitis in an immunocompetent host
por: Hilal, Talal, et al.
Publicado: (2014)

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2016)

Editorial: Pharmacology of infectious diseases: world tuberculosis day 2022
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lo18stggdmv06pdf7l7b46rv1h